MSET - Mindset Pharma discusses decision to expand into non-hallucinogenic drug discovery
(NewsDirect)
Mindset Pharma CEO James Lanthier joinsProactive's Natalie Stoberman to discuss the company's latestupdate to expand into non-hallucinogenic therapeutic drug discovery.
Lanthier says Mindset has been oneof the first biotech companies in the psychedelic space to applystate-of-the-art medicinal chemistry and behavioural pharmacologytechniques to novel scaffolds of psychedelic drugs with the goal ofdiscovering new medicines.
He adds that the company has beenworking towards discovering novel psychedelic-inspirednon-hallucinogenic drug candidates and has found multiple candidateswith a promising preclinical profile.
ContactDetails
Proactive Canada
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.